We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Outlines Quality Requirements for Monoclonal Antibodies
EMEA Outlines Quality Requirements for Monoclonal Antibodies
February 17, 2009
Marketing authorization applications for monoclonal antibodies (MAs) derived from human or animal tissue should include validation of steps taken to reduce the risk of contamination with viruses, a final guideline says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor